Mr. Chapman began his career in the Department of Human Genetics at UCLA, where he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with multiple sclerosis. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing $100 million. During his time at Genzyme, Mr. Chapman’s efforts reshaped the way medicine is practiced when he led Genzyme’s sales initiative into population screening for Fragile X Syndrome.